Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CONX vs AAPG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AAPG Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 9–0 Matrix Metrics)

AAPG Overall Winner 6-Pillar Tally: CONX 1 – 3 AAPG (2 Tie) Matrix Metrics: CONX 0 – 9 AAPG

As of Nov 16, 2026, Ascentage Pharma Group International American Depository Shares (AAPG) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CONX carries a Unified Composite Score of 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin), whereas AAPG carries 49.7/100 (HOLD) at $13.29 (9.4x Forward P/E, -219.5% operating margin).

  • Technical & Structure Timing Caution: CONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CONX vs AAPG
CONX US Equity
CONX
Institutional Equity
$2.66
-11.75% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.88β · 135% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 25.0 Fund 54.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.9%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $4.23 · SMA50: $5.78
AAPG NASDAQ Head-to-Head Winner
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$13.29
-9.1% 1D
Market Cap $1.4B
TTM Revenue $643M
Forward P/E 9.4x
Beta / 30D Vol 1.32β · 70% Vol
Unified Composite Score
49.7 / 100 HOLD
Tech 58.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.0%), weak momentum, RSI 37
RSI-14: 36.8 · SMA20: $14.94 · SMA50: $15.31

6-Pillar Scorecard Institutional Category Breakdown (CONX 1 – 3 AAPG)

Columns: Metric · CONX · AAPG
1. Valuation Multiples AAPG
Forward P/E N/M 9.4x
Trailing P/E N/M 9.4x
PEG Ratio N/M N/M
EV / Revenue N/M 2.1x
2. Growth & Scale AAPG
Revenue Growth (YoY) N/A +29.3%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $643M
Market Cap N/A $1.4B
3. Profitability & Quality AAPG
Gross Margin N/A 93.9%
Operating Margin N/A -219.5%
Net Profit Margin N/A -228.5%
Return on Equity (ROE) N/A -236.6%
4. Balance Sheet & Cash Flow CONX
Cash Generation (TTM) N/A -$1.34B EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $0.89 Book/Sh · -236.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CONX (0) vs AAPG (9)
Institutional Metric CONX AAPG Criterion Row Edge
Market Capitalization
Scale
N/A $1.4B Larger Scale AAPG
Trailing P/E Ratio
Valuation
N/M 9.4x Lower Multiple AAPG
Forward P/E Ratio
Valuation
N/M 9.4x Lower Multiple AAPG
Revenue Growth (YoY)
Growth
N/A +29.3% Higher Growth AAPG
Operating Margin (TTM)
Profitability
N/A -219.5% Higher Margin AAPG
Net Profit Margin
Profitability
N/A -228.5% Higher Margin AAPG
Return on Equity (ROE)
Capital Efficiency
N/A -236.6% Higher ROE AAPG
52-Week Range Position
Momentum
0% ($3–$28) 0% ($13–$34) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
4.88β · 135% Vol 1.32β · 70% Vol Lower Realized Risk AAPG
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 49.7 / 100 (HOLD) Higher Composite AAPG
Trailing 12M Revenue (USD)
Operating Scale
N/A $643M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 93.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$1.34B EBITDA ($0.89 Book/Sh · -236.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AAPG +41.13 pp
CONX: -54.66% · AAPG: -13.53%
3M Horizon AAPG +17.37 pp
CONX: -44.34% · AAPG: -26.97%
6M Horizon AAPG +43.09 pp
CONX: -77.23% · AAPG: -34.14%
1Y Horizon AAPG +30.24 pp
CONX: -88.97% · AAPG: -58.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CONX vs AAPG. Trailing 12-month operating profitability (CONX N/A vs AAPG -219.5%) and valuation multiples (CONX N/M vs AAPG 9.4x Forward P/E) are benchmarked directly in Pillar 4 below.

CONX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
AAPG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$643M
Gross Margin93.9%
Op. Margin-219.5%
ROE / Fwd P/E-236.6% · 9.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CONX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CONX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AAPG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAPG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CONX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AAPG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and -219.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CONX vs AAPG Key Questions & Quantitative Answers

As of Nov 16, 2026, Ascentage Pharma Group International American Depository Shares (AAPG) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CONX carries a Unified Composite Score of 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin), whereas AAPG carries 49.7/100 (HOLD) at $13.29 (9.4x Forward P/E, -219.5% operating margin). Technical & Structure Timing Caution: CONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AAPG leads the Growth & Scale pillar: CONX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AAPG at +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin). On trailing 12-month operating scale, CONX generates N/A in USD-normalized revenue versus $643M for AAPG. In operating R&D and SG&A reinvestment, CONX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AAPG.

AAPG screens cheaper on headline valuation multiples. CONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AAPG trades at 9.4x Forward P/E, 9.4x Trailing P/E, N/M PEG, and 2.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CONX (N/A ROE) versus AAPG (-236.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CONX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.88β · 135% Vol realized risk). By comparison, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.32β · 70% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.